Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 20210114000000
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients.
The urine albumin-to-creatinine ratio (uACR) is an easy and reliable method of ruling out proteinuria >500 mg per day among patients with systemic light chain (AL) amyloidosis, performing relatively well against the 24-hour urine protein collection (24hUP) gold standard, a recent study has found.
The proximal ureteral diameter is a significant predictor of high-grade ureteral injury during ureteral access sheath placement, with a smaller diameter increasing the risk and severity of such injury, according to a recent study.
In the treatment of patients with acute renal colic, paracetamol and parecoxib are equally effective at dulling pain, reducing the need for rescue analgesia with minimal adverse events, as shown in a study.
Androgen deprivation therapy (ADT) in men with prostate cancer increases the risk of dementia and Alzheimer’s disease, reveals a recent study. Such risk further increases when said treatment is given for more than 12 months.
Adherence to healthy dietary patterns is associated with a reduced risk of erectile dysfunction (ED) particularly among younger men (ie, <60 years), a study has shown, suggesting that a healthy diet may play a role in maintaining erectile function.
New drug applications approved by US FDA as of 16 - 31 December 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Treatment with darolutamide significantly improved overall survival (OS) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a prespecified final analysis of the ARAMIS* study presented at ESMO Asia 2020.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.